Robert Lin
Direktor/Vorstandsmitglied bei Code Biotherapeutics, Inc.
Ursprung des Netzwerks ersten Grades von Robert Lin
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.
9
| Holding Company | Biotechnology | 9 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Robert Lin
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
NAVIDEA BIOPHARMACEUTICALS, INC. | Medical Specialties | Chairman | |
MedImmune Ventures, Inc.
MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures, Inc. ( Medimmune Ventures) is a venture capital firm founded in 2002 by Ron Laufer, Wayne Hockmeyer and David Mott . The firm is headquartered in Gaithersburg, Maryland. | Investment Managers | Private Equity Investor | |
RetroSense Therapeutics LLC
RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Medical Specialties | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Chief Investment Officer | |
University of Oxford | College/University | Graduate Degree | |
University of Rhode Island | College/University | Doctorate Degree | |
University of London | College/University | Graduate Degree | |
LaSalle University | College/University | Undergraduate Degree Undergraduate Degree | |
Franklin & Marshall College | College/University | Undergraduate Degree | |
Union College (New York) | College/University | Undergraduate Degree | |
Moscow State University Lomonosov | College/University | Undergraduate Degree Masters Business Admin | |
Villanova University | College/University | Masters Business Admin | |
Stiefel Laboratories, Inc.
Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree | |
Sidney Kimmel Medical College | College/University | Doctorate Degree | |
Licensing Executives Society | Corporate Officer/Principal | ||
Genisphere LLC
Genisphere LLC Electronic Equipment/InstrumentsElectronic Technology Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Whiz Partners, Inc.
Whiz Partners, Inc. Investment ManagersFinance Whiz Partners, Inc. (Whiz Partners) is an independent venture capital firm headquartered in Tokyo, Japan. It became a separate entity from its former brand, CSK Venture Capital Co., Ltd. The firm was founded by Toshio Ando, Atsushi Matsumura, and Junichi Kajimoto in 2010. | Investment Managers | Director/Board Member | |
Max Planck Institute of Biochemistry | College/University | Doctorate Degree | |
Corporate Fuel Partners LLC
Corporate Fuel Partners LLC Investment ManagersFinance Corporate Fuel Partners LLC (Corporate Fuel Partners) is a private equity subsidiary of Corporate Fuel Advisors LLC Founded in 2005. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
Westcon Group AS
Westcon Group AS Trucks/Construction/Farm MachineryProducer Manufacturing Westcon Group AS provides solutions, services, and products within the offshore, energy, and maritime industry. The firm offers technical facilities, such as floating docks, deepwater quays for three drilling rigs, high payload cranes, and machinery. Its services include power and automation, lifting techniques, rig repairs, international rig service, offshore, ship repairs, subsea, pipe technology, engineering, 3D solutions and turbo services. The company was founded in 2011 and is headquartered in Olensvag, Norway. | Trucks/Construction/Farm Machinery | Corporate Officer/Principal | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
Harvard Business School | College/University | Masters Business Admin | |
VIKING THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
SHATTUCK LABS, INC. | Biotechnology | Director/Board Member | |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
4bio Capital Partners | Investment Managers | Private Equity Investor | |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
PASSAGE BIO, INC. | Biotechnology | Corporate Officer/Principal | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Pharmaceuticals: Major | Director/Board Member | |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Adaptate Biotherapeutics Ltd.
Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Pharmaceuticals: Major | Director/Board Member | |
IgniteEye Corp.
IgniteEye Corp. Packaged SoftwareTechnology Services IgniteEye Corp. engages in the provision of cloud services for recruitment activities. Its cloud products include SONAR, Compass, Sniping and CREATIVE. The company was founded by Takashi Yoshida in May 2013 and is headquartered in Tokyo, Japan. | Packaged Software | Director/Board Member | |
Axcelead Drug Discovery Partners, Inc.
Axcelead Drug Discovery Partners, Inc. Miscellaneous Commercial ServicesCommercial Services Axcelead Drug Discovery Partners, Inc. is a Japanese company founded in 2017 that provides services for the quality evaluation of new modality regenerative medical cells, effectiveness and safety evaluation of target cells, and bridging data. The company is based in Fujisawa, JP. and has subsidiaries in the United States. It is used by more than 100 facilities such as clients pharmaceutical companies, venture companies, and academia. Axcelead offers non-clinical development strategic planning and problem resolution services to its clients. | Miscellaneous Commercial Services | Director/Board Member | |
Iron City Micro Display, Inc. | Director/Board Member | ||
Scineuro Pharmaceuticals
Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then. | Biotechnology | Consultant / Advisor | |
SG3 Ventures LLC | President | ||
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Biotechnology | Chief Executive Officer | |
Hornet Therapeutics Ltd.
Hornet Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Hornet Therapeutics Ltd. is a British company founded in 2019 that provides immune cell metabolism and cell therapy for cancer treatment. The company is based in London, UK. | Miscellaneous Commercial Services | Director/Board Member | |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
WatchWire LLC
WatchWire LLC Packaged SoftwareTechnology Services EnergyWatch, Inc. provides energy data management services. It offers energy supply and risk management, utility expense & data management, facility optimization, sustainability reporting and strategic solutions. The company was founded by Jay Raphaelson and Diana Sweeney in 2000 and is headquartered in New York, NY. | Packaged Software | Director/Board Member | |
Hevolution Foundation | Corporate Officer/Principal | ||
82VS | Investment Managers | President |
Statistik
International
Vereinigte Staaten | 32 |
Vereinigtes Königreich | 7 |
Japan | 5 |
Deutschland | 3 |
Russland | 2 |
Sektoral
Health Technology | 14 |
Consumer Services | 14 |
Finance | 9 |
Commercial Services | 7 |
Technology Services | 3 |
Operativ
Director/Board Member | 67 |
Independent Dir/Board Member | 18 |
Corporate Officer/Principal | 13 |
Private Equity Investor | 10 |
Chairman | 7 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Ed Mathers Mathers | 47 |
Brian McVeigh | 15 |
Victor Stone | 12 |
Joseph Truitt | 10 |
Dmitry Kuzmin | 9 |
Yury Kukushkin | 9 |
Russ Fein | 7 |
S. Rouan | 7 |
Erin Brubaker | 4 |
- Börse
- Insiders
- Robert Lin
- Unternehmensverbindungen